Roche Korea’s non-small cell lung cancer treatment Alecensa 150mg Cap. (alectinib hydrochloride) became subject to negotiations under the Price-Volume Agreement (PVA) and will be supplied at a 4.5% discounted price starting next month. Price of Remodulin Inj. (treprostinil) that is used to treat patients with pulmonary arterial hypertension will also be discounted 4% for each strength.

Also, premium pricing on Daewon Pharmaceutical’s Pelubi S Tab. (pelubiprofen tromethamine) will expire on August 1st, after which its price will fall 23.2%.

According to industry sources on the 20th, the Ministry of Health and Welfare planned an ‘Amendment to the drug reimbursement list and reimbursement c